Alzheimer's deal renegotiated Meanwhile Biogen has one of the most keenly anticipated drug candidates in its pipeline, early Alzheimer’s treatment aducanumab. The firm has just renegotiated its ...

The suit claimed that Biogen paid millions of dollars to doctors in the form of speaker honoraria ... the abject failure of Alzheimer's drug and former blockbuster hope Aduhelm (aducanumab ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

Focus remains on Alzheimer's and rare disease markets. Biogen demonstrated solid performance ... to prevent any background noise. After the speakers' remarks, there will be a question and answer ...

We see Biogen as a firm in transition, as MS revenue fades and new drugs for Alzheimer's, depression, and rare diseases begin to ramp up. Biogen generated nearly $6 billion in MS revenue in 2023 ...

CEO Chris Viehbacher reaffirmed Biogen’s priority of driving growth in its four recently launched drugs: Leqembi for early-stage Alzheimer’s disease, Qalsody for benign prostate cancer ...